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Bronchial epithelial cells represent the first line of defense against microorganisms and allergens in the airways and play an
important role in chronic inflammatory processes such as asthma. In an experimental model, both RvD1 and AT-RvD1, lipid
mediators of inflammation resolution, ameliorated some of the most important phenotypes of experimental asthma. Here, we
extend these results and demonstrate the effect of AT-RvD1 on bronchial epithelial cells (BEAS-2B) stimulated with IL-4. AT-RvD1
(100 nM) decreased both CCL2 and CXCL-8 production, in part by decreasing STAT6 and NF-𝜅B pathways. Furthermore, the
effects of AT-RvD1 were ALX/FRP2 receptor dependent, as the antagonist of this receptor (BOC1) reversed the inhibition of these
chemokines by AT-RvD1. In addition, AT-RvD1 decreased SOCS1 and increased SOCS3 expression, which play important roles in
Th1 andTh17 modulation, respectively. In conclusion, AT-RvD1 demonstrated significant effects on the IL-4-induced activation of
bronchial epithelial cells and consequently the potential to modulate neutrophilic and eosinophilic airway inflammation in asthma.
Taken together, these findings identify AT-RvD1 as a potential proresolving therapeutic agent for allergic responses in the airways.
1. Introduction
Asthma is an inflammatory disease of the airways char-
acterized by the migration and accumulation of leuko-
cytes, particularly eosinophils, mucus hypersecretion, and
bronchial hyperreactivity. The pathophysiology of asthma
is coordinated by the immune response of CD4+ T cells,
specifically the Th2 phenotype. IL-4 is the major cytokine
involved in the Th2 immune response. IL-4 uses Janus
kinases (JAKs) to initiate the signaling cascade and activate
signal transducer and activator of transcription 6 (STAT6),
consequently modulating allergic airway inflammation in
asthma andother diseases [1].Most patientswith asthmahave
symptoms that are readily controllable by standard asthma
therapies, including 𝛽2-adrenergic agonists, low doses of
inhaled corticosteroids, or leukotriene modifiers [2]. How-
ever, 5–10% of asthmatic individuals have poorly controlled
disease with frequent exacerbations or symptoms that are
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refractory to current therapy [3]. Th1 andTh17 cells promote
neutrophil recruitment and have been associated with both
severe and steroid-resistant asthma [4].
Bronchial epithelial cells are involved in the homeostasis
and coordination of immune responses in the airways and
represent the first line of defense against microorganisms
and allergens in the lungs [5, 6]. These cells express pattern
recognition receptors, such as Toll-like receptors (TLR),
and protease-activated receptors (PARs), which recognize
microorganisms and allergens, respectively [7, 8]. The acti-
vation of these receptors on epithelial cells induces the
production of chemokines and the expression of adhesion
molecules and cytokines [9, 10] that can influence dendritic
cell maturation, T cell differentiation, and airway inflamma-
tionmodulation [11–14]. Bronchial epithelial cells also express
the receptor for IL-4 (IL-4RA), and the activation of these
cells by IL-4 induces, among other inflammatory parameters
[15], the production of chemokines, for example, CCL2,
CXCL-8, among others [7, 13, 14, 16, 17], which modulate
leukocyte traffic and consequently airway inflammation in
asthma.
During inflammation, the essential omega-3 fatty acid
docosahexaenoic acid (DHA; C22:6) is available for enzy-
matic transformation into several anti-inflammatory and
proresolving mediators, including the class of molecules
termed resolvins [18]. Resolvin and its epimer, Aspirin-
Triggered-Resolvin D1 (AT-RvD1, R configuration at carbon
17), are enzymatically derived from DHA and demonstrate
anti-inflammatory and pro-resolving effects in several exper-
imental models, including in the airways in acute lung injury
[19] and experimental airway allergic inflammation induced
by ovalbumin [20] in mice. In this study, we investigated the
role of AT-RvD1 on bronchial epithelial cells stimulated with
IL-4.
2. Materials and Methods
2.1. Bronchial Epithelial Cells. Thehumanbronchial epithelial
cell line BEAS-2B (ATCC, Rockville, MD) was cultured in
Dulbecco’s modified Eagle’s medium (DMEM-F12/Gibco-
Life Technologies, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (Gibco-Life Technologies) and 1%
penicillin + streptomycin (Gibco-Life Technologies, Carls-
bad, CA, USA) and incubated at 37∘C in a humidified
atmosphere with 5% CO
2
and 95% ambient air.
2.2. Stimulus and Treatment. AT-RvD1 was donated by Dr.
David Bruce Levy of the Harvard Medical School. BEAS-
2B (4 × 104 cell/mL) cells were cultivated in 96-well plates
and treated with AT-RvD1 (1–100 nM) or vehicle (absolute
alcohol) for 30minutes prior to IL-4 (25 ng/mL) [17] stimula-
tion. The use of BOC1 (10 𝜇M), an ALX receptor antagonist,
followed the same experimental procedure described above
but was added 15min before treatment with AT-RvD1 [21].
2.3. CCL2 and CXCL-8 Production in the Supernatant of
Cells TreatedwithAT-RvD1 toChemokineQuantification. The
supernatant was collected at 24 h after IL-4 stimulation, and
the CCL2 and CXCL-8 concentrations were measured by
enzyme-linked immunosorbent assays (ELISA) according to
the manufacturers’ instructions (BD Pharmingen, San Diego,
CA, USA).
2.4. Expression of NF-𝜅B and STAT6 in Cells Treated with AT-
RvD1. The effect of AT-RvD1 on the NF-𝜅B and STAT6 path-
ways was assessed by cytometry according to Cao et al. [22].
Briefly, 15min after IL-4 stimulation, cells were fixedwith pre-
warmedBDCytofixBuffer (4%paraformaldehyde) for 10min
at 37∘C. After centrifugation, the cells were permeabilized in
ice-cold methanol for 30min and then stained with mouse
monoclonal antibodies against anti-NF-𝜅B (BD Biosciences
Pharmingen, Phosflow, USA), anti-STAT6 (BD Biosciences
Pharmingen, Phosflow, USA), or their corresponding mouse
IgG2b isotype (BD Biosciences Pharmingen, Phosflow, USA)
for 60min followed by an FITC- or PE-conjugated goat
anti-mouse IgG2b secondary antibody for another 45min at
10∘C in the dark. The cells were then washed, resuspended,
and subjected to analysis. The expression of intracellular
phosphorylated signalingmolecules in 50,000 viable cells was
analyzed by flow cytometry (FACSCalibur; BD Biosciences
Pharmingen).
The results for phosphorylated NF-𝜅B and STAT6 are
shown as a percentage of fluorescence and are expressed as
the arithmetic mean.
2.5. SOCS1 and SOCS3 Expression. At 1 h after IL-4 stimu-
lation, total RNA was extracted from cells using Pure Linkr
RNA Mini Kit (Life Technologies, Carlsbad, CA, USA).
cDNA was synthesized by reverse transcription (RT) from
total RNA with SuperScript VILO MasterMix ((Invitro-
gen), Carlsbad, CA, USA) according to the manufacturer’s
instructions. Duplicate qPCR reactions were performed with
primers for SOCS1 (Forward: 5󸀠-TTTTTCGCCCTTAGC-
GTGA-3󸀠, Reverse: 5󸀠-AGCAGCTCGAAGAGGCAGTC-3󸀠)
and SOCS3 (Forward: 5󸀠-TGAGCGCGGCTACAGCTT-3󸀠,
Reverse: 5󸀠-TCCTTAATGTCACGCACGATTT-3󸀠) and con-
trol GAPDH (Forward: 5󸀠-CCACCCATGGCAAATTCC-3󸀠,
Reverse: 5󸀠-TCGCTCCTGGAAGATGGTG-3󸀠) (Life Tech-
nologies) using cDNA-specific TaqMan Gene Expression
Assays with an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). In each 5𝜇L TaqMan reaction, cDNA
(corresponding to 100 ng reverse transcribed RNA) was
mixed with 0.25 𝜇L TaqMan Gene Expression Assay, 2.5𝜇L
TaqMan Universal PCR Master Mix (Applied Biosystems),
and 1.25 𝜇L H
2
O. The PCR conditions were 95∘C for 20 s,
followed by 50 cycles at 95∘C for 3 s, and 60∘C for 30 s.
Negative control reactions with no cDNA present and three
interrun calibrator samples were included on each assay plate.
The Ct (cycle threshold) values for SOCS1 and SOCS3
mRNA were normalized to GAPDH to provide the delta Ct
values. The relative mRNA expression was determined using
the Livakmethod (the 2−ΔΔCt method for real-timePCR) [23].
2.6. Statistical Analysis. The results were expressed as the
mean ± standard error of the mean. An evaluation of the
results was performed by an analysis of variance (ANOVA)
followed by a Tukey post-test among the means using
GraphPad PRISM (Version 6.0; GraphPad Software Inc., San
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Figure 1: AT-RvD1 reduced the production of CCL2 (a) and CXCL-8 (b) in bronchial epithelial cells stimulated with IL-4. BEAS-2B cells
were stimulated with IL-4 (25 ng/mL) in the presence or absence of AT-RvD1 (1–100 nM) for 24 h, and the culture supernatants were analyzed
to determine CCL2 and CXCL-8 concentrations using an ELISA kit. The data are reported as the means ± SEM (𝑛 = 7). ∗𝑃 < 0.05 versus
control group; #𝑃 < 0.05 versus IL-4-treated group.
Diego, CA, USA). 𝑃 values less than 0.05 were considered
statistically significant.
3. Results
3.1. AT-RvD1 Reduces the Concentration of Chemokines. The
activation of bronchial epithelial cells induces, among others,
the release of chemokines [7, 13, 14, 16, 17].Therefore, we eval-
uated the role of AT-RvD1 in CCL2 and CXCL-8 production
in bronchial epithelial cells stimulated with IL-4. Our results
showed that IL-4 stimulation (25 ng/mL for 24 h) induced
a prominent increase in CCL2 and CXCL-8 concentrations
compared to nonstimulated cells (control group; Figures 1(a)
and 1(b), resp.). At all doses (1–100 nM), AT-RvD1 signifi-
cantly reducedCCL-2 (Figure 1(a)) andCXCL-8 (Figure 1(b))
production when compared with the cells treated with IL-4,
whereas no significant differencewas observed in cells treated
with vehicle compared to cells treated with IL-4 (data not
shown).
3.2.The Inhibitory Effect of AT-RvD1 onChemokine Production
Is ALX/FPR2 Receptor Dependent. The results presented
above demonstrated that AT-RvD1modulated the chemokine
production induced by IL-4 in bronchial epithelial cells.
Recent findings have shown that AT-RvD1 exerts part of
its proresolving effects via interactions with the ALX/FPR2
receptor present on bronchial epithelial cells [24, 25]. Accord-
ingly, we verified whether the ALX/FPR2-selective antago-
nist, BOC1, is capable of blocking the effects of AT-RvD1 on
chemokine release by BEAS-2B cells after IL-4 stimulation.
As demonstrated above, IL-4 stimulated CCL-2 and CXCL-
8 production, and AT-RvD1 reduced both (Figures 2(a) and
2(b), resp.). Interestingly, BOC1 significantly reversed the
inhibitory effect of AT-RvD1 on CCL2 (Figure 2(a)) and
CXCL-8 (Figure 2(b)) production. No significant difference
was observed in cells stimulated with IL-4 and treated with
BOC1 (10 𝜇M) when compared with cells treated with IL-4.
3.3. AT-RvD1Downregulates the Phosphorylation of Transcrip-
tion Factors. We next evaluated the effect of AT-RvD1 on the
STAT6 and NF-𝜅B pathways. Signal transducer and activator
of transcription 6 (STAT6) and nuclear factor kappa B (NF-
𝜅B) have been demonstrated to regulate many pathologic
features of asthma, and both are activated by IL-4 [26, 27]. As
shown in Figures 3(a) and 3(b), IL-4 induced the significant
phosphorylation of NF-𝜅B and STAT6 in cells compared
to the control. Of note, AT-RvD1 significantly reduced cells
expressing of NF-𝜅B (Figure 3(a)) and STAT6 (Figure 3(b))
when compared to cells treated only with IL-4.
3.4. AT-RvD1 Acts in Modulating the Expression of SOCS1
and SOCS3. As the SOCS family is known to inhibit STAT
signaling, we next evaluated the effect of AT-RvD1 on SOCS1
and SOCS3. In these experiments, the dose of 50 ng/mL
was used for stimulation because the dose of 25 ng/mL
did not induce the SOCSs expression (data not shown);
this is in agreement with previous results [27]. The results
showed that AT-RvD1 significantly reduced the expression
of SOCS1 when compared with cells stimulated with IL-
4 (Figure 4(a)); moreover, AT-RvD1 significantly increased
SOCS3 expression (Figure 4(b)).
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Figure 2: AT-RvD1 reduces CCL2 (a) and CXCL-8 (b) production in BEAS-2B cells stimulated with IL-4 through ALX/FPR2 receptor
activation. BEAS-2B cells were stimulated with IL-4 (25 ng/mL) in the presence or absence of AT-RvD1 (100 nM) or in combination with
BOC1, an ALX selective antagonist (10𝜇M), for 24 h; the culture supernatants were analyzed for CCL2 and CXCL-8 concentrations using an
ELISA kit. The data are reported as the means ± SEM (𝑛 = 7). ∗𝑃 < 0.05 versus control group, #𝑃 < 0.05 versus IL-4-treated group, and
+
𝑃 < 0.05 versus IL-4 + AT-RvD1(100 nM) treated group.
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Figure 3: AT-RvD1 downregulates the NF-𝜅B (a) and STAT6 (b) pathways in bronchial epithelial cells stimulated with IL-4. BEAS-2B cells
were stimulated with IL-4 (25 ng/mL) for 15min in the presence or absence of AT-RvD1 (100 nM).The results are expressed as the arithmetic
mean plus SEM from three independent experiments (𝑛 = 4). ∗𝑃 < 0.05 versus control group; #𝑃 < 0.05 versus IL-4-treated group.
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Figure 4: AT-RvD1 decreases SOCS1 (a) and increases SOCS3 (b) expression in bronchial epithelial cells stimulated with IL-4 (50 ng/mL).
BEAS-2B cells were treated with AT-RvD1 (100 nM) 30 minutes before IL-4 stimulation. At 1 hour after stimulation, SOCS expression was
quantified by qPCR. The results are expressed as the mean ± EPM (𝑛 = 4). ∗𝑃 < 0.05 versus IL-4.
4. Discussion
IL-4 coordinates the Th2 immune response, which is associ-
ated with the pathophysiology of asthma. Interesting lipids
mediators of resolution, such as AT-RvD1, demonstrate
significant anti-inflammatory and proresolution effects in
several experimental models. Here, we demonstrate for the
first time the effect of AT-RvD1 in bronchial epithelial cells
stimulated with IL-4. AT-RvD1 significantly reduced CCL2
and CXCL-8 production when compared to cells treated with
IL-4. These effects are ALX/FPR2 receptor dependent and in
part associatedwith the downregulation of STAT6 andNF-𝜅B
pathways by AT-RvD1.Therefore, AT-RvD1 decreased SOCS1
and increased SOCS3 expression, which play critical roles in
lymphocyte differentiation, maturation, and function. These
results suggest that AT-RvD1 can modulate the innate and
adaptive immune responses of asthma and other diseases, but
further studies are needed for confirmation.
IL-4 is the major factor in the differentiation of the
Th2-type immune response and blocks the differentiation
of Th1 cells by indirect inhibiting interferon-𝛾 (IFN-𝛾) [28].
Bronchial epithelial cells express IL-4 receptor (IL-4R), and
IL-4 induces the production of chemokines such as CCL2
and CXCL-8, among other inflammatory parameters [7,
22, 24–26]. CCL2, also known as monocyte chemotactic
protein-1 (MCP-1), is a potent chemotactic for monocytes
and is produced constitutively or after stimulation in various
cell types, including bronchial epithelial cells [27]. Indeed,
CCL2 is chemotactic to monocytes/macrophages, basophils,
eosinophils, and Th2 cells. In addition, CCL2 is involved in
the polarization of Th2 cells and therefore is associated with
the pathogenesis of allergic inflammatory diseases, such as
asthma [29, 30]. Most patients with asthma have symptoms
that are readily controllable by standard asthma therapies
[2]. However, 5–10% of asthmatic individuals have poorly
controlled disease with frequent exacerbations or symptoms
that are refractory to current therapy [2, 3]. Distinct from
the airway inflammation of stable asthma, which has been
attributed to ongoing Th2-mediated inflammation, with a
predominance of eosinophils and lymphocytes, there is
increasing evidence to suggest that the increased inflamma-
tion in asthma exacerbation is under different regulation
[31]. In addition to the eosinophils and lymphocytes that
predominate in Th2-type inflammation, asthma exacerba-
tions are notable for a neutrophil-enriched inflammatory
response, which in some cases is the principal cellular
infiltrate. Neutrophils are the major inflammatory cell in
the airways of individuals dying within several hours of
an asthma attack and are found in increasing numbers in
patients dying of status asthmaticus [32]. Their numbers are
increased in the sputum and bronchial washings of patients
intubated for status asthmaticus [33–35]. There are several
chemoattractants for neutrophils, such as the CXCL-8 [36]
and the lipid mediator leukotriene B4 (LTB
4
) [37]. CXCL-
8 is a chemokine that is mainly involved in the recruitment
of neutrophils and exerts this effect by binding to two cell
surface receptors, chemokine receptors CXCR1 and CXCR2
[36]. In addition to neutrophils, CXCL-8 may also recruit B
and T lymphocytes, NK cells, and dendritic cells [38–40]. In
addition, CXCL-8 induces the degranulation of neutrophils,
basophils, and macrophages [41].
LTB
4
and proinflammatory lipids mediators are well
known to play important roles in asthma [42], but not all lipid
mediators are associated with inflammation. For example,
lipoxins and resolvins and their epimers are lipids mediators
generated during the resolution phase and demonstrate
significant anti-inflammatory and proresolution effects [43,
44]. In a previous study, our group demonstrated that AT-
RvD1 markedly decreased airway eosinophilia and mucus
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metaplasia, in part by decreasing IL-5 and IkB𝛼 degradation
in allergen-sensitized and challenged mice. In addition, AT-
RvD1 significantly enhanced themacrophage phagocytosis of
IgG-OVA-coated beads in vitro and in vivo, a new proresolv-
ingmechanism for the clearance of allergens from the airways
[20]. In the present work, AT-RvD1 significantly reduced
CCL2 and CXCL-8 production in bronchial epithelial cells
when compared to cells stimulated with IL-4, demonstrating
the potential to reduce both neutrophilic and eosinophilic
inflammation in asthma.
AT-RvD1 can serve as an agonist for theALX/FPR2 recep-
tor to transduce, in part, its proresolution action [45–48].The
ALX/FPR2 receptor is broadly expressed in airway epithelial
cells and alveolar macrophages and is dynamically regulated
during allergic airway responses, leading to decreased recep-
tor abundance [20, 49]. These changes are similar to those
observed in human asthma [50]. We demonstrated that the
inhibitory effect of AT-RvD1 on chemokine production by
BEAS-2B cells stimulated with IL-4 is ALX/FPR2 receptor
dependent, because the antagonist of this receptor reversed
its effects.
Several transcription factors have also been impli-
cated in the inflammatory process of asthma, including
STAT6 and NF-𝜅B [51–54]. STAT6 has been demonstrated
to regulate many pathologic features of lung inflamma-
tory responses, including Th2 cell differentiation, airway
eosinophilia, epithelial mucus production, and smooth mus-
cle changes [55, 56]. NF-𝜅B controls the expression of
some relevant genes encoding chemokines (CCL11, CXCL-
8), cytokines (IL-5), and adhesion molecules (P-selectin)
involved in airway eosinophilic and/or neutrophilic inflam-
mation [57–60]. AT-RvD1 demonstrated a significant effect
in reducing the phosphorylation of both STAT6 and NF-𝜅B
in BEAS-2B cells stimulated with IL-4. The downregulation
of NF-𝜅B by AT-RvD1 is in agreement with a previous study
by our group [19, 20]; however, the present study is the first
to demonstrate STAT6 modulation by AT-RvD1.
The JAK/STAT pathways have a pivotal role in the
differentiation of helper T cells. The SOCS family, induced
by cytokine stimulation, inhibits STAT signaling [59, 60].
SOCS1 has been shown to be a critical negative regulator
of IFN-𝛾 and consequently of the Th1 immune response
[61]. SOCS3 promotesTh2 differentiation by blocking STAT4
signaling. However, the removal of SOCS3 from T cells
inhibits Th1 and Th2 responses [62, 63]. In addition, SOCS3
blocks STAT3 signaling and consequently inhibits Th17
polarization [64]. IL-17 plays an important role in the
development of severe asthma due to induced neutrophilic
inflammation [65, 66]. Therefore, the inhibition of Th17
cell differentiation or IL-17 production could be beneficial
for controlling severe asthma. SOCS plays an important
role in the modulation of inflammation and is critical due
to its broad spectrum of signaling events. However, the
role of SOCS in bronchial epithelial cells is not clear. In
our experiments, IL-4 increased both SOCS1 and SOCS3
expression, with SOCS1 showing higher expression, whereas
AT-RvD1 decreased SOCS1 and increased SOCS3 expression
compared to cells stimulated with IL-4. Thus, it is possible
that SOCS1 inhibition and SOCS3 induction, involved in
Th1 and Th17 immune responses, respectively, by AT-RvD1
may also negatively regulate JAK/STAT signaling pathways
in BEAS-2B cells. However, additional studies are needed to
test this hypothesis. Taken together, the results suggested that
AT-RvD1 has a potential to modulate the immune response
in both stable and severe asthma.
5. Conclusion
In conclusion, our results demonstrate that AT-RvD1 mod-
ulates the activation of bronchial epithelial cells induced by
IL-4. AT-RvD1, via the ALX/FPR2 receptor, decreased CCL2
and CXCL-8 production and downregulated the NF-𝜅B and
STAT6 pathways. In addition, AT-RvD1 decreased SOCS1
and increased SOCS3 expression. Together, these results
suggest that AT-RvD1 has the potential to control airway
inflammation.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This work was supported by grants from the Conselho
Nacional de Desenvolvimento Cient´ıfico e Tecnolo´gico
(CNPq) (no. 475349/2010-5), Fundac¸a˜o de Apoio a Pesquisa
do Estado de Minas Gerais (FAPEMIG) (no. 01/11 CDS APQ
01631/11), Rede de Pesquisa emDoenc¸as InfecciosasHumanas
eAnimais do Estado deMinasGerais (codeREDE20/12), and
Universidade Federal do TriaˆnguloMineiro (UFTM), Brazil.
References
[1] A. E. Kelly-Welch, E.M. Hanson,M. R. Boothby, and A. D. Kee-
gan, “Interleukin-4 and interleukin-13 signaling connections
maps,” Science, vol. 300, no. 5625, pp. 1527–1528, 2003.
[2] C. H. Fanta, “Asthma,” The New England Journal of Medicine,
vol. 360, no. 10, pp. 1002–1014, 2009.
[3] W.W. Busse and R. F. Lemanske Jr., “Asthma,”TheNew England
Journal of Medicine, vol. 344, no. 5, pp. 350–362, 2001.
[4] C. M. Lloyd and E. M. Hessel, “Functions of T cells in asthma:
more than just T
𝐻
2 cells,” Nature Reviews Immunology, vol. 10,
no. 12, pp. 838–848, 2010.
[5] H. Hammad and B. N. Lambrecht, “Dendritic cells and epithe-
lial cells: linking innate and adaptive immunity in asthma,”
Nature Reviews Immunology, vol. 8, no. 3, pp. 193–204, 2008.
[6] Q. Sha, A. Q. Truong-Tran, J. R. Plitt, L. A. Beck, and R.
P. Schleimer, “Activation of airway epithelial cells by toll-like
receptor agonists,” American Journal of Respiratory Cell and
Molecular Biology, vol. 31, no. 3, pp. 358–364, 2004.
[7] A. Kato, S. Favoreto Jr., P. C. Avila, and R. P. Schleimer, “TLR3-
and Th2 cytokine-dependent production of thymic stromal
lymphopoietin in human airway epithelial cells,”The Journal of
Immunology, vol. 179, no. 2, pp. 1080–1087, 2007.
[8] H. F. Kauffman, “Innate immune responses to environmental
allergens,” Clinical Reviews in Allergy and Immunology, vol. 30,
no. 2, pp. 129–140, 2006.
BioMed Research International 7
[9] N. Bilyk and P. G. Holt, “Inhibition of the immunosuppres-
sive activity of resident pulmonary alveolar macrophages by
granulocyte/macrophage colony-stimulating factor,” Journal of
Experimental Medicine, vol. 177, no. 6, pp. 1773–1777, 1993.
[10] C. Ebeling, T. Lam, J. R. Gordon, M. D. Hollenberg, and H.
Vliagoftis, “Proteinase-activated receptor-2 promotes allergic
sensitization to an inhaled antigen through a TNF-mediated
pathway,” The Journal of Immunology, vol. 179, no. 5, pp. 2910–
2917, 2007.
[11] A. Kiss, M. Montes, S. Susarla et al., “A new mechanism regu-
lating the initiation of allergic airway inflammation,” Journal of
Allergy and Clinical Immunology, vol. 120, no. 2, pp. 334–342,
2007.
[12] P. A. Stumbles, D. H. Strickland, C. L. Pimm et al., “Regulation
of dendritic cell recruitment into resting and inflamed airway
epithelium: use of alternative chemokine receptors as a function
of inducing stimulus,” Journal of Immunology, vol. 167, no. 1, pp.
228–234, 2001.
[13] C. M. Lilly, H. Nakamura, H. Kesselman et al., “Expression of
eotaxin by human lung epithelial cells: induction by cytokines
and inhibition by glucocorticoids,” The Journal of Clinical
Investigation, vol. 99, no. 7, pp. 1767–1773, 1997.
[14] J. Reibman, Y. Hsu, L. C. Chen, B. Bleck, and T. Gordon,
“Airway epithelial cells release MIP-3𝛼/CCL20 in response to
cytokines and ambient particulate matter,” American Journal of
Respiratory Cell and Molecular Biology, vol. 28, no. 6, pp. 648–
654, 2003.
[15] D. C.Webb, Y. Cai, K. I.Matthaei, and P. S. Foster, “Comparative
roles of IL-4, IL-13, and IL-4R𝛼 in dendritic cell maturation and
CD4+ Th2 cell function,” The Journal of Immunology, vol. 178,
no. 1, pp. 219–227, 2007.
[16] F. Q. Wen, T. Kohyama, X. Liu et al., “Interleukin-4- and
interleukin-13-enhanced transforming growth factor-𝛽2 pro-
duction in cultured human bronchial epithelial cells is attenu-
ated by interferon-𝛾,” The American Journal of Respiratory Cell
and Molecular Biology, vol. 26, no. 4, pp. 484–490, 2002.
[17] W. K. Ip, C. K. Wong, and C. W. K. Lam, “Interleukin (IL)-
4 and IL-13 up-regulate monocyte chemoattractant protein-
1 expression in human bronchial epithelial cells: Involvement
of p38 mitogen-activated protein kinase, extracellular signal-
regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-
terminal kinase 1/2 signalling pathways,” Clinical and Experi-
mental Immunology, vol. 145, no. 1, pp. 162–172, 2006.
[18] C. N. Serhan, S. Hong, K. Gronert et al., “Resolvins: a family of
bioactive products of omega-3 fatty acid transformation circuits
initiated by aspirin treatment that counter proinflammation
signals,” The Journal of Experimental Medicine, vol. 196, no. 8,
pp. 1025–1037, 2002.
[19] O. Eickmeier, H. Seki, O. Haworth et al., “Aspirin-triggered
resolvin D1 reduces mucosal inflammation and promotes res-
olution in a murine model of acute lung injury,” Mucosal
Immunology, vol. 6, no. 2, pp. 256–266, 2013.
[20] A. P. Rogerio, O. Haworth, R. Croze et al., “Resolvin D1 and
aspirin-triggered resolvin D1 promote resolution of allergic
airways responses,” The Journal of Immunology, vol. 189, no. 4,
pp. 1983–1991, 2012.
[21] C. Bonnans, D. Gras, C. Chavis et al., “Synthesis and anti-
inflammatory effect of lipoxins in human airway epithelial
cells,” Biomedicine and Pharmacotherapy, vol. 61, no. 5, pp. 261–
267, 2007.
[22] J. Cao, C. K. Wong, Y. Yin, and C. W. K. Lam, “Activation of
human bronchial epithelial cells by inflammatory cytokines IL-
27 and TNF-𝛼: Implications for immunopathophysiology of
airway inflammation,” Journal of Cellular Physiology, vol. 223,
no. 3, pp. 788–797, 2010.
[23] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene
expression data using real-time quantitative PCR and the 2-
ΔΔCT method,”Methods, vol. 25, no. 4, pp. 402–408, 2001.
[24] J. C. Porter and A. Hall, “Epithelial ICAM-1 and ICAM-2
regulate the egression of human T cells across the bronchial
epithelium,” FASEB Journal, vol. 23, no. 2, pp. 492–502, 2009.
[25] A. B. Thompson, R. A. Robbins, D. J. Romberger et al.,
“Immunological functions of the pulmonary epithelium,” Euro-
pean Respiratory Journal, vol. 8, no. 1, pp. 127–149, 1995.
[26] F.-Q. Wen, T. Kohyama, X. Liu et al., “Interleukin-4- and
interleukin-13-enhanced transforming growth factor-𝛽2 pro-
duction in cultured human bronchial epithelial cells is attenu-
ated by interferon-𝛾,” American Journal of Respiratory Cell and
Molecular Biology, vol. 26, no. 4, pp. 484–490, 2002.
[27] D. Wu, W. Tan, Q. Zhang, X. Zhang, and H. Song, “Effects
of ozone exposure mediated by BEAS-2B cells on T cells
activation: a possible link between environment and asthma,”
Asian Pacific Journal of Allergy and Immunology, vol. 32, no. 1,
pp. 25–33, 2014.
[28] T. Nakamura, Y. Kamogawa, K. Bottomly, and R. A. Flavell,
“Polarization of IL-4- and IFN-𝛾-producing CD4 + T cells
following activation of naive CD4+ T cells,” The Journal of
Immunology, vol. 158, no. 3, pp. 1085–1094, 1997.
[29] D. Hebenstreit, P. Luft, A. Schmiedlechner et al., “IL-4 and IL-13
induce SOCS-1 gene expression inA549 cells by three functional
STAT6-binding motifs located upstream of the transcription
initiation site,” The Journal of Immunology, vol. 171, no. 11, pp.
5901–5907, 2003.
[30] L. Gu, S. Tseng, R.M.Horner, C. Tam,M. Loda, andB. J. Rollins,
“Control of T
𝐻
2 polarization by the chemokine monocyte
chemoattractant protein-1,”Nature, vol. 404, no. 6776, pp. 407–
411, 2000.
[31] “Proceedings of the ATS workshop on refractory asthma:
current understanding, recommendations, and unanswered
questions. American Thoracic Society,” American Journal of
Respiratory and Critical Care Medicine, vol. 162, no. 6, pp. 2341–
2351, 2000.
[32] S. Sur, T. B. Crotty, G. M. Kephart et al., “Sudden-onset fatal
asthma: a distinct entity with few eosinophils and relatively
more neutrophils in the airway submucosa?” American Review
of Respiratory Disease, vol. 148, no. 3, pp. 713–719, 1993.
[33] J. V. Fahy, K.W.Kim, J. Liu, andH.A. Boushey, “Prominent neu-
trophilic inflammation in sputum from subjects with asthma
exacerbation,” Journal of Allergy and Clinical Immunology, vol.
95, pp. 843–852, 1995.
[34] C. Lamblin, P. Gosset, I. Tillie-Leblond et al., “Bronchial
neutrophilia in patients with noninfectious status asthmaticus,”
American Journal of Respiratory and Critical Care Medicine, vol.
157, no. 2, pp. 394–402, 1998.
[35] S. H. Twaddell, P. G. Gibson, K. Carty, K. L. Woolley, and R.
L. Henry, “Assessment of airway inflammation in children with
acute asthma using induced sputum,” European Respiratory
Journal, vol. 9, no. 10, pp. 2104–2108, 1996.
[36] F. M. Konrad and J. Reutershan, “CXCR2 in acute lung injury,”
Mediators of Inflammation, vol. 2012, Article ID 740987, 8 pages,
2012.
8 BioMed Research International
[37] K. F. Chung, “Inflammatory mediators in chronic obstructive
pulmonary disease,” Current Drug Targets: Inflammation and
Allergy, vol. 4, no. 6, pp. 619–625, 2005.
[38] T. C. Allen and A. Kurdowska, “Interleukin 8 and acute lung
injury,” Archives of Pathology and Laboratory Medicine, vol. 138,
no. 2, pp. 266–269, 2014.
[39] N. Todorovic´-Rakovic´ and J. Milovanovic´, “Interleukin-8 in
breast cancer progression,” Journal of Interferon and Cytokine
Research, vol. 33, no. 10, pp. 563–570, 2013.
[40] B. Dhooghe, S. Noe¨l, F. Huaux, and T. Leal, “Lung inflammation
in cystic fibrosis: pathogenesis and novel therapies,” Clinical
Biochemistry, vol. 47, no. 7-8, pp. 539–546, 2014.
[41] M. J. Stuart and B. T. Baune, “Chemokines and chemokine
receptors in mood disorders, schizophrenia, and cognitive
impairment: a systematic review of biomarker studies,” Neuro-
science & Biobehavioral Reviews, vol. 42, pp. 93–115, 2014.
[42] E. H. Chung, Y. Jia, H. Ohnishi et al., “Leukotriene B4 receptor
1 is differentially expressed on peripheral T cells of steroid-
sensitive and -resistant asthmatics,” Annals of Allergy, Asthma
and Immunology, vol. 112, no. 3, pp. 211–216, 2014.
[43] C. N. Serhan, “Novel lipid mediators and resolution mech-
anisms in acute inflammation: to resolve or not?” American
Journal of Pathology, vol. 177, no. 4, pp. 1576–1591, 2010.
[44] C. D. Russell and J. Schwarze, “The role of pro-resolution lipid
mediators in infectious disease,” Immunology, vol. 141, no. 2, pp.
166–173, 2014.
[45] S. Krishnamoorthy, A. Recchiuti, N. Chiang et al., “Resolvin
D1 binds human phagocytes with evidence for proresolving
receptors,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 107, no. 4, pp. 1660–1665, 2010.
[46] L. V. Norling, J. Dalli, R. J. Flower, C. N. Serhan, and M.
Perretti, “Resolvin D1 limits polymorphonuclear leukocyte
recruitment to inflammatory loci: receptor-dependent actions,”
Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 32, no. 8,
pp. 1970–1978, 2012.
[47] S. Krishnamoorthy, A. Recchiuti, N. Chiang, G. Fredman, and
C.N. Serhan, “ResolvinD1 receptor stereoselectivity and regula-
tion of inflammation and proresolving MicroRNAs,” American
Journal of Pathology, vol. 180, no. 5, pp. 2018–2027, 2012.
[48] M. Perretti, N. Chiang, M. La et al., “Endogenous lipid- and
peptide-derived anti-inflammatory pathways generated with
glucocorticoid and aspirin treatment activate the lipoxin A4
receptor,” Nature Medicine, vol. 8, no. 11, pp. 1296–1302, 2002.
[49] B. Wang, X. Gong, J.-Y. Wan et al., “Resolvin D1 protects mice
from LPS-induced acute lung injury,” Pulmonary Pharmacology
andTherapeutics, vol. 24, no. 4, pp. 434–441, 2011.
[50] A. Planaguma`, S. Kazani, G. Marigowda et al., “Airway lipoxin
A4 generation and lipoxinA4 receptor expression are decreased
in severe asthma,” The American Journal of Respiratory and
Critical Care Medicine, vol. 178, no. 6, pp. 574–582, 2008.
[51] P. J. Barnes and I. M. Adcock, “Glucocorticoid resistance in
inflammatory diseases,”TheLancet, vol. 373, no. 9678, pp. 1905–
1917, 2009.
[52] Q. Guo, Y. Xu, and Z. Zhang, “Role of activator protein-1 in
the transcription of interleukin-5 gene regulated by protein
kinase C signal in asthmatic human T lymphocytes,” Journal of
Huazhong University of Science and Technology, vol. 25, no. 2,
pp. 147–150, 2005.
[53] Y. Nakamura and M. Hoshino, “TH2 cytokines and associated
transcription factors as therapeutic targets in asthma,” Current
Drug Targets: Inflammation and Allergy, vol. 4, no. 2, pp. 267–
270, 2005.
[54] M. E. Poynter, R. Cloots, T. van Woerkom et al., “NF-𝜅B
activation in airways modulates allergic inflammation but not
hyperresponsiveness,” Journal of Immunology, vol. 173, no. 11,
pp. 7003–7009, 2004.
[55] A. Iwata, S. Kawashima, M. Kobayashi et al., “T
ℎ
2-type inflam-
mation instructs inflammatory dendritic cells to induce airway
hyperreactivity,” International Immunology, vol. 26, no. 2, pp.
103–114, 2014.
[56] Q. Fu, J. Wang, Z. Ma, and S. Ma, “Anti-asthmatic effects of
matrine in a mouse model of allergic asthma,” Fitoterapia, vol.
94, pp. 183–189, 2014.
[57] M. E. Rothenberg, A. D. Luster, and P. Leder, “Murine eotaxin:
an eosinophil chemoattractant inducible in endothelial cells
and in interleukin 4-induced tumor suppression,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 92, no. 19, pp. 8960–8964, 1995.
[58] J. Anrather, V. Csizmadia, C. Brostjan, M. P. Soares, F. H. Bach,
andH.Winkler, “Inhibition of bovine endothelial cell activation
in vitro by regulated expression of a transdominant inhibitor of
NF-𝜅B,” The Journal of Clinical Investigation, vol. 99, no. 4, pp.
763–772, 1997.
[59] L. Yang, L. Cohn, D.-H. Zhang, R. Homer, A. Ray, and P.
Ray, “Essential role of nuclear factor 𝜅B in the induction of
eosinophilia in allergic airway inflammation,” The Journal of
Experimental Medicine, vol. 188, no. 9, pp. 1739–1750, 1998.
[60] K. J. Serio, K. V. Reddy, and T. D. Bigby, “Lipopolysaccharide
induces 5-lipoxygenase-activating protein gene expression in
THP-1 cells via a NF-𝜅B and C/EBP-mediated mechanism,”The
American Journal of Physiology—Cell Physiology, vol. 288, no. 5,
pp. 1125–1133, 2005.
[61] E. M. Linossi, J. J. Babon, D. J. Hilton, and S. E. Nicholson,
“Suppression of cytokine signaling: the SOCS perspective,”
Cytokine and Growth Factor Reviews, vol. 24, no. 3, pp. 241–248,
2013.
[62] K. Inagaki-Ohara, T. Kondo, M. Ito, and A. Yoshimura, “SOCS,
inflammation, and cancer,” JAKSTAT, vol. 1, pp. 2–3, 2013.
[63] B. Carow and M. E. Rottenberg, “SOCS
3
: a major regulator of
infection and inflammation,” Frontiers in Immunology, vol. 5,
article 58, 2014.
[64] D. C. Palmer and N. P. Restifo, “Suppressors of cytokine
signaling (SOCS) in T cell differentiation, maturation, and
function,” Trends in Immunology, vol. 30, no. 12, pp. 592–602,
2009.
[65] Y. Li and S. Hua, “Mechanisms of pathogenesis in allergic
asthma: role of interleukin-23,” Respirology, vol. 19, no. 5, pp.
663–669, 2014.
[66] Y. Morishima, S. Ano, Y. Ishii et al., “Th17-associated cytokines
as a therapeutic target for steroid-insensitive asthma,” Clinical
and Developmental Immunology, vol. 2013, Article ID 609395, 9
pages, 2013.
